FGF2 and bone cancer: Therefore, considering the involvement of bFGF in the invasiveness of bone tumors, through activation of the ERK1/2 and MAPK signaling pathways, it was considered appropriate to act by blocking this axis to reduce the morbidity and mortality associated with bone cancer metastases; these assumptions were also confirmed by clinical studies in which high serum levels of bFGF were correlated with poor overall survival [104].